Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| March 31, 2026 | 12 | -146 | -146 | ₹ |
| Dec. 31, 2025 | 16 | -17 | -17 | ₹ |
| Sept. 30, 2025 | 21 | -7 | -7 | ₹ |
| June 30, 2025 | 21 | -5 | -5 | ₹ |
| March 31, 2025 | 26 | — | -5 | ₹ |
| Dec. 31, 2024 | 37 | -6 | -6 | ₹ |
| Sept. 30, 2024 | 25 | -5 | -5 | ₹ |
| June 30, 2024 | 29 | -8 | -8 | ₹ |
| March 31, 2024 | 39 | 7 | 5 | ₹ |
| Dec. 31, 2023 | 41 | -17 | -16 | ₹ |
| Sept. 30, 2023 | 34 | -20 | -20 | ₹ |
| June 30, 2023 | 35 | -16 | -16 | ₹ |
| March 31, 2023 | 37 | -268 | -266 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 70 | -175 | -175 |
| March 31, 2025 | 116 | -31 | -31 |
| March 31, 2024 | 149 | -46 | -45 |
| March 31, 2023 | 187 | -331 | -329 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 8 | -1 | -6 | 0 | 8 |
| March 31, 2025 | -11 | 5 | 5 | -5 | -6 |
| March 31, 2024 | -24 | 28 | -6 | 0 | -24 |
| March 31, 2023 | 14 | -1 | -16 | 1 | 13 |
| March 31, 2022 | -658 | 523 | -10 | 0 | -658 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 753 | -211 | -227 | 326 | 72 | 168 | 448 | 0 | 237 | 13 |
| March 31, 2025 | 921 | — | — | — | — | 328 | 408 | 1 | 254 | 59 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
